Investor Overview ABOUT Organovo Holdings

New Post Public Reply Private Reply Replies (0) Message Board
Badali

Investor Overview

ABOUT Organovo Holdings Inc. (OTCQX: ONVO)

Organovo designs and creates functional, three-dimensional human tissues for medical research and therapeutic applications. We are collaborating with pharmaceutical and academic partners to develop human biological disease models in three dimensions. These 3D human tissues have the potential to accelerate the drug discovery process, enabling treatments to be developed faster and at lower cost. Organovo is changing the shape of medical research and practice.

ORGANOVO HIGHLIGHTS

  • Organovo develops the world’s first commercial 3D bioprinting technology platform.
  • Organovo reported in April 2013 on the creation of the first fully cellular 3D bioprinted liver tissue.
  • Organovo named to MIT Technology Review’s 2012 TR50 List of World’s Most Innovative Companies.
  • Organovo’s NovoGen MMX Bioprinter named one of the “Best Inventions of 2010” by TIME Magazine.
  • Organovo partners with Autodesk Research to develop 3D bioprinting software.
  • Organovo has been featured in leading publications and media outlets, including: The Wall Street Journal, The Economist, The New York Times online, Nature, Science, TIME Magazine, Businessweek, Fast Company, Inc. Magazine, WIRED, Forbes, MIT Technology Review, CNBC, Discovery Channel, ABC News, and CBS Sunday Morning.

IMPACTS: Drug Discovery & Development

The drug discovery process requires new tools that can provide better insight into how a drug will perform in human clinical trials. Drug discovery and development is very expensive, especially when a drug fails later in clinical trials due to toxicity or ineffectiveness.

A new drug, on average, costs $1.2 billion and takes 12 years to develop. Each year, the pharmaceutical industry spends more than $50 billion on research and development, and approximately 20 new drugs are approved by the FDA. Organovo’s 3D bioprinting technology has the potential to significantly impact the speed and predictiability of drug discovery.

IMPACTS: Transplant Medicine

Organovo’s 3D bioprinting technology also holds great promise for creating direct tissue therapies. More than 114,300 people are waiting for an organ transplant. Last year, fewer than 5,000 transplants took place. Approximately 18 people die each day waiting for an organ. Our long-term goal is to create tissues intended for direct therapeutic use to augment or replace damaged or degenerating organs.

ORGANOVO’S APPROACH

Organovo’s near-term applications are to develop functional 3D human tissues for drug discovery and toxicology testing, because Organovo-produced living tissue provides:

  • Better disease models than animals and cells alone
  • Better recreation of human biology with in vitro convenience
  • Acceleration of drug discovery using 3D human tissues that reproduce the natural microenvironment

The technology is able to create, without the use of scaffolding, 3D anatomically correct tissues with integrated microvasculature. This structural organization of the multiple cell types typical to tissue composition results in tissue-level responses and physiologic processes found in native biology.

3D BIOPRINTING

Growth: The bioprinting process involves taking cells from a research cell line, a patient or other sources and growing them in culture until enough cells are present.

Collection & Formation: The cells are then collected and specially incubated in order to help the cells form bio-ink, consisting of cells and the building blocks to form a functional organ system in vitro. This is the beginning stage of solid tissue formation.

Printing: The cell mixture is loaded into a cartridge, which is then placed into the printer. With a computer-programmed script, the printer deposits the tissue into desired shape. The printed tissue is incubated for 48 hours or more to allow it to mature.

Use: The tissue can be used in a number of research applications, such as drug discovery or toxicology testing. The goal is to replicate human physiology for research, drug testing and, eventually, as therapies. To date, Organovo has worked with several tissue types including blood vessels, cardiac muscle and lung tissue.

partnerships

Our academic and pharmaceutical partnerships advance the discovery, development, and use of 3D human tissues and enable scientists to obtain cellular-level data within the context of a living tissue. Our technology platform helps partners:

  • Test the effects of compounds or treatments on human tissues in 3D to understand their roles in human physiology and disease
  • Create unique and powerful ways to investigate multiple in vivo systems of interest
  • Solve complex research problems and fill next-generation pipelines
  • Study disease and identify pathways in a whole new way

We have rapidly developed and produced tissues that can be used in a variety of applications, including 3D models that recapitulate human liver, human vasculature and human small airway. We have also demonstrated that our bioprinted tissues can respond to biomechanical and soluble stimuli, resulting in tissue-level responses that encompass multiple cell types and physiologic processes.

We are currently helping pharmaceutical and academic partners develop 3D human tissues for disease research, drug discovery and development, and toxicity testing. We currently have collaborative partnerships with multiple pharmaceutical companies, including Pfizer, and leading research institutions, including Harvard Medical School, Oregon Health Sciences University Knight Cancer Institute, and the Sanford Consortium for Regenerative Medicine.

Organovo Holdings, Inc. (ONVO) Stock Research Links

ONVO Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Apotex Enters U.S. Market with Axitinib Tablets Launch

Updated Category News Views 114

Apotex's Bold Move: Axitinib Tablets Hit the U.S. Market Apotex is shaking things up in the pharma world by launching the first generic version of Axitinib Tablets in the U.S., aimed at treating advanced renal cell carcinoma (RCC) when previous treatments have fallen flat. This isn't just another dance with the red tape—it's a major step for Apotex, flexing their muscle...

Continue Reading
Rock & Roll Hall of Fame's 2026 Induction Triumph

Updated Category News Views 180

A Night of Unstoppable Talent The Rock & Roll Hall of Fame's 2026 Induction Ceremony and boy, what a spectacle it was. Held on a lively Saturday night, November 14, in Los Angeles, it wasn't just an event; it was an electrifying testament to music's profound impact. With the grand ceremony kicking off at the historic city of stars, this year's induction turned the dial to...

Continue Reading
Ross Pools Joins Forces with Florida Panthers in 2026

Updated Category News Views 104

An Unlikely Team-Up: Pools and Hockey Well, here's one for the books: a South Florida pool company hitching its wagon to an NHL team. Ross Pools, the folks who’ve been carving out backyard oases in the sizzling Florida sun for over two decades, are now officially aligned with the Florida Panthers. Yeah, the same Panthers that snatched the Stanley Cup not once but twice...

Continue Reading
Biotech Hit or Miss: Trials and Tribulations

Updated Category News Views 96

Biotech's Roller Coaster: Triumphs and Setbacks Ah, the biotech sector—it's a bit like jumping on a bull, ain't it? You barely hang on when the beast bucks. Monday's market action was downright wild. The S&P 500 didn't have a party, tumbling 1.92%, and the Nasdaq wasn't any friendlier, plummeting 2.49%. Yet, inside this storm, we see some biotech names either catching...

Continue Reading
Hermes AI: A New Era in Market Analysis?

Updated Category News Views 111

Revolution or Just Another App? In a world where stock market insights are as cryptic as hieroglyphs to the average Joe, here comes the Hermes AI Analyzer, breaking onto the scene and promising to translate Wall Street's complex lingo into plain, simple language. It's the brainchild of Turkish engineer Umut Tugrul, who has spent decades in the trenches of software...

Continue Reading
Loyalty Programs Cut $1500 Annually for Consumers

Updated Category News Views 132

Loyalty Programs: An Essential Tool for Households In a world where every dollar counts, retail loyalty programs have become more than just a marketing strategy—they're lifelines for American households scraping through each month. According to fresh research by the Retail Industry Leaders Association (RILA) and conducted by market research leader Circana, these...

Continue Reading
Luxury Villa Cashback Offers Entice Travelers in November

Updated Category News Views 134

A November Bonanza for Villa Bookings Who doesn't love having a few extra bucks in their pocket, especially when they come with the allure of luxury travel? Villas of Distinction is rolling out what they call a 'November Cashback Offer,' and for those with the wallet—and wanderlust—to match, it could be a tempting proposition. Hanging the bait of up to $2,000 cashback...

Continue Reading
Teamsters Ratify Contract, Averting Waste Strike

Updated Category News Views 117

Big Win for Teamsters Local 350 You ever seen a strike averted by sheer willpower and unity? That’s what's happened here with the workers at South San Francisco Scavenger Company. These folks—drivers, mechanics, sorters, and utility workers—all banded together under the Teamsters Local 350 and showed management what's what by securing a contract they deserve. We're...

Continue Reading
Webull Faces FINRA Fine and Legal Battle Ahead

Updated Category News Views 187

Webull's Compliance Headache Webull’s been knocked around again. This time, the Financial Industry Regulatory Authority (FINRA) slapped it with a hefty $4.2 million fine. Talk about a hit to the wallet! It all boils down to them failing to roll out some basic anti-money laundering (AML) and other crucial compliance programs. This is no small oversight, and it's got...

Continue Reading
Ainstein Expands Kansas Operations Amid Sensor Demand Surge

Updated Category News Views 133

Ainstein's Expansion Conquers New Heights in Radar Tech Ainstein just cranked open a whole new chapter right in the heart of Kansas. And believe me, it's not your average ribbon-cutting story. This shiny new facility in Lenexa is locked and loaded to roll out 44,000 radar sensors a year. It's part of a no-nonsense plan to keep up with soaring demand for their tech across...

Continue Reading

Top 5 Most Recently Viewed Articles

Unlocking the Future of Health with ELMCRx and ETS Partnership

Updated Category News Views 154

ELMCRx Solutions and ETS Partnership ELMCRx Solutions is forging new paths within the healthcare landscape through its strategic alliance with Emerging Therapy Solutions (ETS). This collaboration is tailored to address the innovative and costly challenges posed by cell and gene therapies (CGT). ELMCRx stands out as a pharmacy benefit manager (PBM) dedicated to providing...

Continue Reading
International Symposium on Microbes and Cancer Research

Updated Category News Views 203

International Symposium on Microbes and Cancer Research Set for March 2-3, the upcoming conference promises to bring together globally recognized experts from various fields related to cancer science. The event, hosted by Tampa General Hospital (TGH) Cancer Institute and the USF Health Morsani College of Medicine, will highlight critical intersections between microbes,...

Continue Reading
Freddie Mac Welcomes Matthew Abrusci as New General Counsel

Updated Category News Views 314

Freddie Mac Names Matthew Abrusci as General Counsel MCLEAN, Va. — Freddie Mac (OTCQB: FMCC) proudly announces the appointment of Matthew D. Abrusci as its new Executive Vice President, General Counsel, and Corporate Secretary. With his extensive experience in financial services, Abrusci is set to make significant contributions to the organization. Matthew Abrusci's...

Continue Reading
Energizer Holdings Declares Increased Dividend for Shareholders

Updated Category News Views 188

Energizer Holdings Announces Dividend for Shareholders Energizer Holdings, Inc. (NYSE: ENR) recently declared a quarterly dividend, highlighting the company’s ongoing dedication to its investors. The Board of Directors determined that each share of common stock will receive a dividend of $0.30, reflecting the organization's solid performance and commitment to returning...

Continue Reading
Tevogen Bio: Pioneering Cost-Effective Innovations in Biopharma

Updated Category News Views 199

Tevogen Bio's Innovative Approach to Healthcare As the biopharma sector navigates an increasingly competitive landscape, Tevogen Bio Holdings Inc. (NASDAQ: TVGN) stands out for its commitment to delivering groundbreaking medical solutions while maintaining affordability. This dedication is crucial as international competitors, particularly from China, develop drugs more...

Continue Reading